NDAOPHTHALMICSUSPENSION/DROPS
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
Drug data last refreshed 21h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BETOPTIC S is a topical ophthalmic suspension containing betaxolol hydrochloride, a selective beta-1 adrenergic antagonist used to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The drug works by decreasing aqueous humor production through beta-adrenergic blockade in the eye. It has been a mainstay of glaucoma therapy since its approval in 1989.
$0.675MPart D
LOE ApproachingDeclining market position with LOE approaching signals reduced headcount expansion and shift toward brand defense rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension
Started Jan 2019
366 enrolled
Primary Open-angle GlaucomaOcular Hypertension
Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension
Started Jan 2003
105 enrolled
GlaucomaOcular Hypertension
Career Relevance
Working on BETOPTIC S offers limited growth but valuable experience in defending mature products in a competitive landscape and managing market access in specialty ophthalmology. This role emphasizes relationship management, formulary positioning, and lifecycle optimization rather than launch excitement or breakthrough innovation.
Worked on BETOPTIC S at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.